AMERICAN CYANAMID's JACK BOWMAN MOVING TO JOHNSON & JOHNSON
Executive Summary
AMERICAN CYANAMID's JACK BOWMAN MOVING TO JOHNSON & JOHNSON to take responsibility for J&J's core pharmaceutical business. As a J&J company group chairman, Bowman will oversee McNeil Pharmaceutical Ortho Pharmaceutical, and Cilag, J&J's European pharmaceutical group. Bowman's resignation from American Cyanamid was announced July 21. He will officially join J&J on Aug. 1. At American Cyanamid, Bowman was executive vice president heading the $1.4 bil. medical group, consisting of Lederle pharmaceuticals and the medical device operations, including Davis & Geck. Under Bowman, the Cyanamid medical businesses have been growing rapidly. Medical group earnings in 1986 were up 28% to $184 mil. ("The Pink Sheet" May 18, p. 5). In the July 21 press release, American Cyanamid CEO George Sella said "Bowman leaves a long legacy of strong research and development, marketing, manufacturing and organization."